Chronic obstructive pulmonary disease: new opportunities for drug development.
Chronic obstructive pulmonary disease (COPD) is common and there is an increasing worldwide prevalence. There are no available treatments to prevent the progression of airflow obstruction, but greater understanding of the molecular and cellular mechanisms involved in COPD has identified many new therapeutic targets, including inflammatory mediators, proteases and adhesion molecules. In this review, Peter Barnes considers potential new drugs for this neglected disease.
Barnes
P J
PJ
National Heart and Lung Institute, Imperial College School of Medicine, London, UK.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D018942:Macrolides; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D016540:Smoking Cessation
D000318:Adrenergic beta-Agonists; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D018942:Macrolides; D010726:Phosphodiesterase Inhibitors